6-Bromo-2-chlorothiazolo[4,5-b]pyridine

Catalog No.: 
ACMNKK952
CAS No.: 
960535-44-8
Molecular Formula: 
C6H2BrClN2S
Molecular Weight: 
249.52
6-Bromo-2-chlorothiazolo[4,5-b]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$305.00InquiryInquiry
100mg95%$450.00InquiryInquiry
250mg95%$638.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-Bromo-2-chlorothiazolo[4,5-b]pyridine
IUPAC Name6-bromo-2-chlorothiazolo[4,5-b]pyridine
Molecular FormulaC6H2BrClN2S
Molecular Weight249.52
SMILESClC1=NC2=NC=C(C=C2S1)Br
InChI KeyQKBMJZODSYDEFC-UHFFFAOYSA-N
Synonym6-BROMO-2-CHLOROTHIAZOLO[4,5-B]PYRIDINE;Thiazolo[4,5-b]pyridine, 6-bromo-2-chloro-;6-Bromo-2-chloro-[1,3]thiazolo[4,5-b]pyridine
CAS No.960535-44-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACMNKK952 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSCYU023 route compound structure diagram
    ACSCYU023857970-06-0In Stock
  2. Then
  3. ACMNKK952 route product structure diagram
    ACMNKK952960535-44-8
Inquiry

2. ACMNKK952 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACAFDO578 route compound structure diagram
    ACAFDO57835486-42-1In Stock
  4. Then
  5. ACMNKK952 route product structure diagram
    ACMNKK952960535-44-8
Inquiry

3. ACMNKK952 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMNKK952 route product structure diagram
    ACMNKK952960535-44-8
Inquiry

Comments (0)